Literature DB >> 12069997

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Qiu N Sun1, Laura K Najvar, Rosie Bocanegra, David Loebenberg, John R Graybill.   

Abstract

The in vivo activities of posaconazole, itraconazole, and amphotericin B in neutropenic mice with zygomycosis were compared. The in vitro MICs of posaconazole and itraconazole for the strains of Mucor spp. used in this study ranged from 0.125 to 8 microg/ml and 0.25 to 8 microg/ml, respectively. The in vitro MIC range for amphotericin B is 0.125 to 0.25 microg/ml. At twice-daily doses of >or=15 mg/kg of body weight, posaconazole prolonged the survival of the mice and reduced tissue burden.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12069997      PMCID： PMC127310          DOI： 10.1128/AAC.46.7.2310-2312.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Zygomycosis in the 1990s in a tertiary-care cancer center.

Authors:  D P Kontoyiannis; V C Wessel; G P Bodey; K V Rolston
Journal:  Clin Infect Dis       Date:  2000-06-13       Impact factor: 9.079

2.  Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug.

Authors:  L Z Goldani; A M Sugar
Journal:  J Antimicrob Chemother       Date:  1994-02       Impact factor: 5.790

3.  In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.

Authors:  A Gómez-López; M Cuenca-Estrella; A Monzón; J L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2001-12       Impact factor: 5.790

4.  Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion.

Authors:  R Herbrecht; V Letscher-Bru; R A Bowden; S Kusne; E J Anaissie; J R Graybill; G A Noskin; E Andrès; L A Pietrelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-07       Impact factor: 3.267

5.  Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients.

Authors:  V Rickerts; A Böhme; A Viertel; G Behrendt; V Jacobi; K Tintelnot; G Just-Nübling
Journal:  Clin Infect Dis       Date:  2000-10-11       Impact factor: 9.079

Review 6.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

7.  Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole.

Authors:  J Mosquera; P A Warn; J L Rodriguez-Tudela; D W Denning
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

8.  Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients.

Authors:  A Penk; L Pittrow
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

Review 9.  Survival factors in rhino-orbital-cerebral mucormycosis.

Authors:  R A Yohai; J D Bullock; A A Aziz; R J Markert
Journal:  Surv Ophthalmol       Date:  1994 Jul-Aug       Impact factor: 6.048

10.  Rhinocerebral mucormycosis: predisposing factors.

Authors:  J S McNulty
Journal:  Laryngoscope       Date:  1982-10       Impact factor: 3.325
View more
  45 in total

1.  Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea.

Authors:  E Alvarez; D Garcia-Hermoso; D A Sutton; J F Cano; A M Stchigel; D Hoinard; A W Fothergill; M G Rinaldi; F Dromer; J Guarro
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

3.  Rapid susceptibility testing of medically important zygomycetes by XTT assay.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Emmanuel Roilides; Tin Sein; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

4.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Authors:  Nikolaos G Almyroudis; Deanna A Sutton; Annette W Fothergill; Michael G Rinaldi; Shimon Kusne
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

6.  Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method.

Authors:  E López-Oviedo; A I Aller; C Martín; C Castro; M Ramirez; J M Pemán; E Cantón; C Almeida; E Martín-Mazuelos
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

8.  Antifungal therapy of murine Aspergillus terreus infection.

Authors:  John R Graybill; Steve Hernandez; Rosie Bocanegra; Laura K Najvar
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.

Authors:  Rachel Courtney; Sudhakar Pai; Mark Laughlin; Josephine Lim; Vijay Batra
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.

Authors:  Mery Ruíz-Cendoya; Marçal Mariné; M M Rodríguez; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.